Consortium of Early Arthritis Cohorts USA
| Status: | Recruiting |
|---|---|
| Conditions: | Arthritis, Rheumatoid Arthritis |
| Therapuetic Areas: | Rheumatology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/17/2018 |
| Start Date: | December 2014 |
Consortium of Early Arthritis Cohorts USA - A Prospective Cohort Study of Adults With New Consent Inflammatory Arthritis Symptoms to Understand Predictors of Optimal Outcomes
Rheumatoid arthritis (RA) is the most common form of inflammatory arthritis. In the US, it is
estimated that as many as 3 million adults may suffer from the disease. Fortunately in the
last few years, a shift in strategy toward the earlier institution of disease modifying drugs
and the availability of new classes of medications have greatly improved the outcomes that
can be expected by most patients.
The goal of treatment now aims toward achieving the lowest possible level of arthritis
disease activity and even remission, if possible as early on as possible. Research has shown
that this translates into minimized joint damage and enhanced physical function and quality
of life for the RA patient. This also requires that a diagnosis of RA be made as early on as
possible, and herein lies the challenge, i.e. identifying the RA patient early on in the
course of their disease.
estimated that as many as 3 million adults may suffer from the disease. Fortunately in the
last few years, a shift in strategy toward the earlier institution of disease modifying drugs
and the availability of new classes of medications have greatly improved the outcomes that
can be expected by most patients.
The goal of treatment now aims toward achieving the lowest possible level of arthritis
disease activity and even remission, if possible as early on as possible. Research has shown
that this translates into minimized joint damage and enhanced physical function and quality
of life for the RA patient. This also requires that a diagnosis of RA be made as early on as
possible, and herein lies the challenge, i.e. identifying the RA patient early on in the
course of their disease.
Inclusion Criteria:
- Patient was 18 years of age or over at time of referral
- Joint symptoms for < 12 months
- 2+ swollen joints OR 1 swollen joint with one of the following: Rheumatoid Factor > 20
IU, (+) anti-CCP antibody, morning stiffness > 45 minutes, responded to NSAIDs, (+)
MTP squeeze test
We found this trial at
1
site
535 E 70th St
New York, New York 10021
New York, New York 10021
(212) 606-1000
Principal Investigator: Vivian P Bykerk, MD
Phone: 646-714-6307
Hospital for Special Surgery Founded in 1863, Hospital for Special Surgery is the nation
Click here to add this to my saved trials
